ELF is leading the way to discovering new medicines

An EU-and industry-funded project has created an integrated platform which is providing an innovative range of free services, expertise and a huge collection of compounds for researchers who are developing new drugs to treat all types of human diseases.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Gambia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Gambia
  Georgia


 

Published: 26 February 2018  
Related theme(s) and subtheme(s)
Health & life sciencesDrugs & drug processes  |  Medical research
Industrial research
Information societyInformation technology
Innovation
Research policySeventh Framework Programme
SMEs
Countries involved in the project described in the article
Belgium  |  Denmark  |  France  |  Hungary  |  Netherlands  |  Sweden  |  United Kingdom
Add to PDF "basket"

ELF is leading the way to discovering new medicines

Image from the youtube video

© European Lead Factory

The European Lead Factory (ELF) is jointly funded by the EU and industry through the Innovative Medicines Initiative, a public-private partnership. It gives researchers access to a library of compounds and a screening service which can help them identify and validate compounds for use in potential new drugs.

“The ELF allows European researchers to identify chemical matter that can serve either as tool to better understand disease mechanisms or even as a starting point for a drug discovery endeavour,” explains project coordinator Stefan Jaroch. “Usually, academic researchers or small biotech companies do not have access to such high-quality screening resources. So, the ELF provides them with the missing link to translate biological innovations into chemical substances.”

Significant contributions

The project consortium comprises 30 partners, including academic institutions, small and medium-sized enterprises (SMEs) and pharmaceutical companies. The team also includes seven members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) who decided to open up their previously secret compound libraries to kick-start early-stage research into discovering new medicines.

The EFPIA has contributed more than 300 000 compounds to the project’s Joint European Compound Library (JECL), while a further 200 000 compounds – specifically synthesised for the JECL – are being provided by SMEs. As of December 2017, JECL already contained 500 095, taking it over the target of 500 000 set at the start of the project.

Researchers can have their target programmes screened at facilities run by the project’s own European screening centre. They are given access to a selected number of compounds with the highest potential for further development at the researcher’s own initiative – or possibly in collaboration with EFPIA partners.

The library and screening services are already delivering concrete results. More than 4 500 compounds have made it through the screening process and have been handed over to European academics and SMEs for use in drug-development programmes.

Supply and demand

Demand for ELF services continues to grow: from involving researchers in eight countries in 2013, applications have currently been submitted from 18 countries. In total, 200 industry and academic programmes have been planned and 150 screening campaigns carried out with results delivered for two-thirds of applicants to date. Meanwhile, some 250 compounds based on new chemistries are synthesised daily in ELF and are incorporated into the JECL to be screened in relation to potential drug targets.

Project resources are being used to find new drug treatments in many areas of human health, including cancer, metabolic disease, heart disease, inflammation and immunology, and infectious diseases.

“The ELF target portfolio covers a wide range of therapeutic areas with high societal relevance, also including neglected and rare diseases,” adds Jaroch. “Efforts to either understand disease mechanisms or embark on a drug-discovery programme are made with a long-term perspective to bring therapies to the patient.”

The project is already helping Europe’s pharmaceutical sector deliver real progress. In the UK, the University of Sheffield and a Parkinson’s disease charity have established a biotech company called Keapstone Therapeutics to exploit ELF results. There is a similar story in Sweden where the University of Gothenburg has founded a start-up company called ScandiCure AB to fight diabetes.

In addition, an ELF programme has been taken further into preclinical development within the EU-backed ENABLE project, which aims to find new drugs to combat bacterial infections. In fact, ELF compounds have already entered the preclinical phase for developing treatments for multi-resistant bacteria and cancer.

By providing such valuable resources to the EU’s science community, ELF is playing a leading role in delivering the innovative services and expertise necessary to find and innovative new drugs to the benefit of researchers, the medical industry and patients alike.

Project details

  • Project acronym: ELF (EUC2LID)
  • Participants: Germany, Belgium, Denmark, France, Hungary, Netherlands, Sweden, United Kingdom
  • Project N°: 115489
  • Total costs: € 194 305 898
  • EU contribution: € 79 999 157
  • Duration: January 2013 to December 2017

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details